The safety of accelerated infusion versus standard rate infusion of low-molecular-weight iron dextran in patients with chronic kidney disease

NDT Plus

Volumn 2, Issue 5, 2009, Pages 432-433

  Sinha, Smeeta ^a   Chiu, Diana Y Y ^a   Peebles, George ^b   Kolakkat, Shabeer ^a   Lamerton, Elizabeth ^a   Fenwick, Sean ^b   Kalra, Philip A ^a  

^a SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^b CITY HOSPITALS SUNDERLAND NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENIRAMINE; COSMOFER; FERRIC HYDROXIDE SUCROSE; HYDROCORTISONE; IRON DEXTRAN; LOW MOLECULAR WEIGHT IRON DEXTRAN; PARACETAMOL; UNCLASSIFIED DRUG;

ACCELERATED INFUSION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; ERYTHEMA; HUMAN; INTERMETHOD COMPARISON; IRON THERAPY; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARD RATE INFUSION; TREATMENT OUTCOME; URTICARIA;

EID: 77956036426     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfp073     Document Type: Letter

References (3)

1. Auerbach M. Ferumoxytol as a new, safer, easier-to-administer intravenous iron: yes or no? Am J Kidney Dis 2008; 52: 826-829
2. Auerbach M, Winchester J, Wahab A et al. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kidney Dis 1998; 31: 81-86
3. Bhandari S, Naudeer S. Improving efficiency and value in health care: intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. J Eval Clin Pract 2008; 14: 996-1001